Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
EML4 - ALK Alectinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK ALK V1180L ALK G1202R Alectinib large cell neuroendocrine carcinoma predicted - resistant detail...
EML4 - ALK ALK V1180L ALK G1202R Brigatinib large cell neuroendocrine carcinoma predicted - resistant detail...
EML4 - ALK ALK V1180L ALK G1202R Lorlatinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK Crizotinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK ALK V1180L Alectinib large cell neuroendocrine carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196M Brigatinib large cell neuroendocrine carcinoma no benefit detail...
EML4 - ALK ALK L1196M ALK G1202R ALK D1203N Lorlatinib large cell neuroendocrine carcinoma predicted - resistant detail...
ALK rearrange Alectinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK Alectinib + Zoledronic acid large cell neuroendocrine carcinoma predicted - sensitive detail...
BRAF G469R Dabrafenib + Trametinib large cell neuroendocrine carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib large cell neuroendocrine carcinoma predicted - sensitive detail...
EML4 - ALK Brigatinib large cell neuroendocrine carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Withdrawn USA 0
NCT04079712 Phase II Cabozantinib + Ipilimumab + Nivolumab Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors Active, not recruiting USA | CAN 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Unknown status ITA 0
NCT04429087 Phase I BI 764532 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 Recruiting USA | ESP | DEU 1
NCT05599984 Phase I ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors Recruiting USA | ITA | ISR | FRA | ESP | DEU | AUS 2
NCT05652686 Phase I PT217 A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Recruiting USA 0
NCT05882058 Phase II BI 764532 DAREO-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT06132113 Phase I BI 764532 + Cisplatin + Etoposide BI 764532 + Carboplatin + Etoposide DAREON-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers Recruiting USA | SWE | NLD | FRA | ESP | DEU | BEL 1
NCT06176989 Phase II Enasidenib Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Recruiting USA 0
NCT06418087 Phase II Carboplatin + Durvalumab + Etoposide Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (DUPLE) Recruiting ITA 0